Therapy for H. pylori infection.
The discovery that peptic ulcers can be caused by gastroduodenal infection with Helicobacter pylori and cured by eradication of this bacterial presence has made a profound impact on ulcer management. This article reviews the principles behind such treatment and the regimens in current use, including proton pump inhibitor triple therapies and ranitidine bismuth citrate triple therapies.
Thomson
A B
AB
Nutrition and Metabolism Research Group, Division of Gastroenterology, 519 Newton Research Building, University of Alberta, Edmonton, AB T6G 2C2, Canada.
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D001729:Bismuth / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D054328:Proton Pump Inhibitors; D011899:Ranitidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D013272:Stomach Diseases / Q000188:drug therapy / Q000382:microbiology
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000897:Anti-Ulcer Agents; D054328:Proton Pump Inhibitors; C073340:ranitidine bismuth citrate; D011899:Ranitidine; D001729:Bismuth